Valeant Pharmaceuticals International, Inc.
Thesis
Ackman is open to hearing contrary views on Valeant, indicating that he is aware of the significant debate surrounding the stock and is willing to consider opposing perspectives.
Did it work?
inconclusive
confidence: low
This is not an actionable investment thesis: it states no direction (long/short), no price target, and no horizon, and merely observes that Ackman was open to contrary views on Valeant. With no price performance data, unknown elapsed time, and no verifiable thesis events provided, there is no basis to judge success or failure.